Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species...

Area of Science:

• Cardiovascular Research
• Molecular Medicine
• Pharmacology

Background:

• Post-myocardial infarction heart failure (post-MI HF) is a significant cause of mortality with limited therapeutic options.
• Honokiol (HK) has shown promise in mitigating myocardial ischemia/reperfusion injury and hypertrophy.
• The potential of HK in treating post-MI HF warrants investigation.

Purpose of the Study:

• To investigate the therapeutic efficacy of Honokiol (HK) in a mouse model of post-myocardial infarction heart failure (post-MI HF).
• To elucidate the underlying molecular mechanisms of HK's cardioprotective effects, focusing on oxidative stress and mitochondrial function.
• To determine the role of mitochondrial uncoupling protein 3 (Ucp3) in mediating HK's benefits.

Main Methods:

• Induction of myocardial infarction (MI) in mice followed by HK administration.
• Assessment of cardiac function, myocardial fibrosis, and reactive oxygen species (ROS) levels.
• In vitro studies using neonatal cardiomyocytes to evaluate HK's effects on mitochondrial membrane potential (MMP) and apoptosis.
• RNA sequencing (RNAseq) to identify HK-modulated gene expression, particularly Ucp3.
• Validation of Ucp3's role using cardiomyocytes with impaired Ucp3 expression and Ucp3 knockout mice.

Main Results:

• HK treatment significantly improved cardiac function, reduced myocardial fibrosis, and inhibited ROS production in post-MI mice.
• HK protected neonatal cardiomyocytes against peroxide-induced damage by maintaining MMP and reducing apoptosis.
• RNAseq analysis revealed that HK significantly upregulated the expression of mitochondrial uncoupling protein 3 (Ucp3).
• The protective effects of HK were abolished in cardiomyocytes with impaired Ucp3 and in Ucp3 knockout mice post-MI.
• HK's ability to increase Ucp3 expression was crucial for its beneficial effects on ROS levels and cardiac function.

Conclusions:

• Honokiol (HK) demonstrates significant therapeutic potential for treating post-myocardial infarction heart failure (post-MI HF).
• HK exerts its cardioprotective effects by upregulating mitochondrial uncoupling protein 3 (Ucp3), which inhibits ROS production and preserves mitochondrial function.
• Targeting Ucp3 with HK represents a promising strategy for managing heart failure following myocardial infarction.